索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]王之文,吴思,蔡东东,等.ARNI在急性心肌梗死后心房颤动发生中的作用[J].国际心血管病杂志,2024,06:346-349.
点击复制

ARNI在急性心肌梗死后心房颤动发生中的作用(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2024年06期
页码:
346-349
栏目:
综述
出版日期:
2024-12-10

文章信息/Info

Title:
-
作者:
王之文; 吴思; 蔡东东; 胡敏; 高新春
223600 徐州医科大学附属沭阳医院心血管内科
Author(s):
-
关键词:
血管紧张素受体脑啡肽酶抑制剂; 急性心肌梗死; 心房颤动
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2024.06.005
文献标识码:
-
摘要:
血管紧张素受体脑啡肽酶抑制剂（ARNI）能有效改善急性心肌梗死（AMI）及心力衰竭患者预后，但其抗心律失常的机制尚不明确，有研究发现ARNI可减少心房颤动的发生率。该文介绍ANRI抑制AMI患者出现新发心房颤动的潜在机制以及基础和临床研究。
Abstract:
-

参考文献/References

[1] Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge[J]. Int J Stroke, 2021, 16(2):217-221.
[2] Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for Cardio-Thoracic surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC[J]. Eur Heart J, 2021, 42(5):373-498.
[3] Wang A, Green JB, Halperin JL, et al. Atrial fibrillation and diabetes mellitus: JACC review topic of the week[J]. J Am Coll Cardiol, 2019, 74(8):1107-1115.
[4] Burnett H, Earley A, Voors AA, et al. Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network Meta-Analysis[J]. Circ Heart Fail, 2017, 10(1):e003529.
[5] Wang J, Yang YM, Zhu J. Mechanisms of new-onset atrial fibrillation complicating acute coronary syndrome[J]. Herz, 2015, 40 Suppl 1:18-26.
[6] Wang ZW, Bao W, Cai DD, et al. Construction of a predictive model for new-onset atrial fibrillation after acute myocardial infarction based on P-wave amplitude in Lead V1[J]. J Electrocardiol, 2024, 83:56-63.
[7] Bahouth F, Mutlak D, Furman M, et al. Relationship of functional mitral regurgitation to new-onset atrial fibrillation in acute myocardial infarction[J]. Heart, 2010, 96(9):683-688.
[8] Savelieva I, Kakouros N, Kourliouros A, et al. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part Ⅱ: secondary prevention[J]. Europace, 2011, 13(5):610-625.
[9] McMurray JJV, Packer M, Desai AS, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) [J]. Eur J Heart Fail, 2013, 15(9):1062-1073.
[10] Packer M. Neurohormonal antagonists are preferred to an implantable cardioverter-defibrillator in preventing sudden death in heart failure[J]. JACC Heart Fail, 2019, 7(10):902-906.
[11] Ambrosy AP, Braunwald E, Morrow DA, et al. Angiotensin receptor-neprilysin inhibition based on history of heart failure and use of renin-angiotensin system antagonists[J]. J Am Coll Cardiol, 2020, 76(9):1034-1048.
[12] Russo V, Bottino R, Rago A, et al. The effect of sacubitril/valsartan on device detected arrhythmias and electrical parameters among dilated cardiomyopathy patients with reduced ejection fraction and implantable cardioverter defibrillator[J]. J Clin Med, 2020, 9(4):1111.
[13] Zhu TY, Zhang WC, Yang Q, et al. Effect of angiotensin receptor-neprilysin inhibitor on atrial electrical instability in atrial fibrillation[J]. Front Cardiovasc Med, 2022, 9:1048077.
[14] Ishii M, Kaikita K, Sato K, et al. Cardioprotective effects of LCZ696 (sacubitril/valsartan) after experimental acute myocardial infarction[J]. JACC Basic Transl Sci, 2017, 2(6):655-668.
[15] Chang KC, Trayanova NA. Mechanisms of arrhythmogenesis related to calcium-driven alternans in a model of human atrial
[16] Bers DM. Cardiac sarcoplasmic reticulum calcium leak: basis and roles in cardiac dysfunction[J]. Annu Rev Physiol, 2014, 76:107-127.
[17] Liu B, Lou Q, Smith H, et al. Conditional up-regulation of SERCA2a exacerbates RyR2-dependent ventricular and atrial arrhythmias[J]. Int J Mol Sci, 2020, 21(7):2535.
[18] Wang HL, Zhou XH, Li ZQ, et al. Prevention of atrial fibrillation by using sarcoplasmic reticulum calcium ATPase pump overexpression in a rabbit model of rapid atrial pacing[J]. Med Sci Monit, 2017, 23:3952-3960.
[19] Yan JJ, Bare DJ, DeSantiago J, et al. JNK2, a newly-identified SERCA2 enhancer, augments an arrhythmic Ca2＋SR leak-load relationship[J]. Circ Res, 2021, 128(4):455-470.
[20] Cai SS, Zhao MY, Zhou B, et al. Mitochondrial dysfunction in macrophages promotes inflammation and suppresses repair after myocardial infarction[J]. J Clin Invest, 2023, 133(4):e159498.
[21] Mohammed Abdulsalam T, Hasanin AH, Hussein Mohamed R, et al. Angiotensin receptor-neprilysin inhibitor (thiorphan/irbesartan) improved cardiac function in a rat model of myocardial ischemic reperfusion injury[J]. Fundam Clin Pharmacol, 2023, 37(1):31-43.
[22] Hajra A, Ujjawal A, Sud K, et al. Sacubitril/valsartan averts post-myocardial infarction ventricular remodeling and preserves heart function[J]. Int J Cardiol Heart Vasc, 2019, 22:218-219.
[23] Forte M, Marchitti S, Di Nonno F, et al. NPPA/atrial natriuretic peptide is an extracellular modulator of autophagy in the heart[J]. Autophagy, 2023, 19(4):1087-1099.
[24] Oi Y, Nagoshi T, Kimura H, et al. Exogenous ANP treatment ameliorates myocardial insulin resistance and protects against ischemia-reperfusion injury in diet-induced obesity[J]. Int J Mol Sci, 2022, 23(15):8373.
[25] Raffa S, Forte M, Gallo G, et al. Atrial natriuretic peptide stimulates autophagy/mitophagy and improves mitochondrial function in chronic heart failure[J]. Cell Mol Life Sci, 2023, 80(5):134.
[26] Santulli G, Xie WJ, Reiken SR, et al. Mitochondrial Calcium overload is a key determinant in heart failure[J]. Proc Natl Acad Sci U S A, 2015, 112(36):11389-11394.
[27] Nso N, Bookani KR, Metzl M, et al. Role of inflammation in atrial fibrillation: a comprehensive review of current knowledge[J]. J Arrhythm, 2021, 37(1):1-10.
[28] Xiao FP, Wang L, Liu M, et al. Sacubitril/valsartan attenuates myocardial ischemia/reperfusion injury via inhibition of the GSK3β/NF-κB pathway in cardiomyocytes[J]. Arch Biochem Biophys, 2022, 730:109415.
[29] Bunsawat K, Ratchford SM, Alpenglow JK, et al. Sacubitril-valsartan improves conduit vessel function and functional capacity and reduces inflammation in heart failure with reduced ejection fraction[J]. J Appl Physiol (1985), 2021, 130(1):256-268.
[30] Sobiborowicz-Sadowska AM, Kamińska K, Cudnoch-J?drzejewska A. Neprilysin inhibition in the prevention of anthracycline-induced cardiotoxicity[J]. Cancers (Basel), 2023, 15(1):312.
[31] Bettoni M, Zimmermann M. Autonomic tone variations before the onset of paroxysmal atrial fibrillation[J]. Circulation, 2002, 105(23):2753-2759.
[32] Ieda M, Fukuda K. New aspects for the treatment of cardiac diseases based on the diversity of functional controls on cardiac muscles: the regulatory mechanisms of cardiac innervation and their critical roles in cardiac performance[J]. J Pharmacol Sci, 2009, 109(3):348-353.
[33] Sayer G, Bhat G. The renin-angiotensin-aldosterone system and heart failure[J]. Cardiol Clin, 2014, 32(1):21-32, vii.
[34] D'Elia E, Iacovoni A, Vaduganathan M, et al. Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides[J]. Eur J Heart Fail, 2017, 19(6):710-717.
[35] Sutanto H, Dobrev D, Heijman J. Angiotensin receptor-neprilysin inhibitor (ARNI) and cardiac arrhythmias[J]. Int J Mol Sci, 2021, 22(16):8994.
[36] Cheng WH, Lugtu IC, Chang SL, et al. Effects of angiotensin receptor-neprilysin inhibitor in arrhythmogenicity following left atrial appendage closure in an animal model[J]. Cardiovasc Drugs Ther, 2021, 35(4):759-768.
[37] Li Q, Fang Y, Peng DW, et al. Sacubitril/valsartan reduces susceptibility to atrial fibrillation by improving atrial remodeling in spontaneously hypertensive rats[J]. Eur J Pharmacol, 2023, 952:175754.
[38] Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure[J]. N Engl J Med, 2019, 380(6):539-548.
[39] Abumayyaleh M, Demmer J, Krack C, et al. Incidence of atrial and ventricular arrhythmias in obese patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan[J]. Diabetes Obes Metab, 2023, 25(10):2999-3011.
[40] Dong YZ, Xiao SC, He JW, et al. Angiotensin receptor-neprilysin inhibitor therapy and recurrence of atrial fibrillation after radiofrequency catheter ablation: a propensity-matched cohort study[J]. Front Cardiovasc Med, 2022, 9:932780.

备注/Memo

备注/Memo:
通信作者：高新春，E-mail：1161530826@qq.com
更新日期/Last Update: 2024-12-10